Routine invasive procedures for stable heart disease found to offer no long-term survival advantage over drug therapy

An international study (ISCHEMIA-EXTEND) found that early invasive procedures like stents or bypass surgery for stable coronary artery disease do not improve long-term survival compared to initial drug therapy and lifestyle changes. While invasive procedures can ease symptoms and improve quality of life, death rates after nearly a decade were essentially the same for both approaches.
Why it matters
This research challenges the long-held assumption that early invasive procedures extend life for stable heart disease patients, potentially influencing treatment guidelines and patient choices by emphasizing conservative approaches first. It suggests that for stable patients, quality of life improvements, rather than survival benefits, are the primary advantage of early invasive interventions.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: CC0 Public Domain Patients with stable heart disease and abnormal stress tests who have invasive procedures early in their care do not live longer than those initially treated with drugs and lifestyle changes alone, an international study shows.
The findings build on results from the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial, which evaluated more than 5,000 men and women with stable coronary artery disease. In this condition, fatty buildup narrows arteries and limits blood flow but does not cause the sudden complete blockage seen in a heart attack.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in